share_log

Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

康乃德生物 | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  06/12 16:52

Moomoo AI 已提取核心訊息

Connect Biopharma Holdings Limited has announced significant changes in its executive leadership. On June 10, 2024, Zheng Wei, Ph.D., and Wubin Pan, Ph.D., communicated their intentions to resign from their respective roles as Chief Executive Officer and President of the company, effective June 12, 2024. Both executives are expected to continue serving in a transitional capacity post-resignation. Concurrently, the Board appointed Kleanthis G. Xanthopoulos, Ph.D., as the new Chairperson of the Board. Furthermore, Barry Quart, Pharm.D., with a notable background including leadership roles at Heron Therapeutics and Ardea Biosciences, has been appointed as the new CEO and a member of the Board. David Szekeres, with previous experience at Heron Therapeutics and Regulus Therapeutics, has been named the new President...Show More
Connect Biopharma Holdings Limited has announced significant changes in its executive leadership. On June 10, 2024, Zheng Wei, Ph.D., and Wubin Pan, Ph.D., communicated their intentions to resign from their respective roles as Chief Executive Officer and President of the company, effective June 12, 2024. Both executives are expected to continue serving in a transitional capacity post-resignation. Concurrently, the Board appointed Kleanthis G. Xanthopoulos, Ph.D., as the new Chairperson of the Board. Furthermore, Barry Quart, Pharm.D., with a notable background including leadership roles at Heron Therapeutics and Ardea Biosciences, has been appointed as the new CEO and a member of the Board. David Szekeres, with previous experience at Heron Therapeutics and Regulus Therapeutics, has been named the new President. These appointments coincide with the adoption of the 2024 Employment Inducement Incentive Award Plan, which is designed to provide incentives to new employees under Nasdaq rules. The plan initially reserves 4,500,000 shares for issuance under awards. The company has also entered into employment agreements with Dr. Quart and Mr. Szekeres, detailing their compensation, bonus eligibility, and severance terms.
Connect Biopharma Holdings Limited宣佈其高管領導層發生重大變化。2024年6月10日,鄭偉博士和潘武斌博士宣佈辭去首席執行官和總裁的職務,辭職時間爲2024年6月12日。預計兩位高管將在辭職後繼續以過渡性的身份服務。與此同時,董事會任命Kleanthis G. Xanthopoulos博士爲新任董事會主席。此外,曾在Heron Therapeutics和Ardea Biosciences擔任領導職務的Barry Quart博士被任命爲新任首席執行官和董事會成員。David Szekeres曾在Heron Therapeutics和Regulus Therape...展開全部
Connect Biopharma Holdings Limited宣佈其高管領導層發生重大變化。2024年6月10日,鄭偉博士和潘武斌博士宣佈辭去首席執行官和總裁的職務,辭職時間爲2024年6月12日。預計兩位高管將在辭職後繼續以過渡性的身份服務。與此同時,董事會任命Kleanthis G. Xanthopoulos博士爲新任董事會主席。此外,曾在Heron Therapeutics和Ardea Biosciences擔任領導職務的Barry Quart博士被任命爲新任首席執行官和董事會成員。David Szekeres曾在Heron Therapeutics和Regulus Therapeutics工作,任命爲新任總裁。這些任命與採納2024年就業誘因激勵獎計劃同時實行,該計劃旨在根據納斯達克的規定爲新員工提供激勵措施。該計劃最初保留4,500,000股股份供獎勵使用。該公司還與Quart博士和Szekeres先生簽訂了就業協議,詳細說明了他們的薪酬、獎金資格和解僱條款。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息